GlycoCheck has been named one of the Top 10 Diabetes Care Solution Providers in 2020 by MedTech Outlook.
“With its commitment to enhancing treatment options for the most urgent medical needs, GlycoCheck and Microvascular Health Solutions is moving the needle in microvascular health and ensuring quality care for all,” reported MedTech Outlook (click to read the article).
The medical technology publication also acknowledges how GlycoCheck is revolutionizing microvascular health, writing “GlycoCheck facilitates reliable, non-invasive identification of individuals at risk and allows monitoring of microvascular health in patients with different conditions and diseases, including but not limited to diabetes, hypertension, heart disease, inflammatory diseases, stroke, and kidney disease.”
MedTech Outlook writes that “the combined efforts of GlycoCheck and Microvascular Health Solutions’ monitoring systems, along with the Endocalyx natural supplement, is proving to be a boon in positively impacting the health of people affected by the coronavirus.”
The publication went on to report about a new study where GlycoCheck was used to evaluate microcirculation and capillary loss in COVID-19 patients. Microvascular Dysfunction in COVID-19: the MYSTIC Study, (click link to read the full study) released by Angiogenesis, found that patients who were on mechanical ventilation had up to 95% of severe damage in the smallest of capillaries. Another group of patients who were hospitalized, but not requiring ventilation, had severe damage to 65% of capillaries. With such a large percentage of the smallest capillaries having been severely damaged, oxygen cannot be transported from the lungs to the rest of the body.